LFCR

SEC source: 0001628280-23-020831 · wk-form4_1685992567.xml · nonDerivative · entry 1

EDWARDS JEFFREY L · CIK 0001190642 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,113

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date).

SEC source: 0001628280-23-020828 · wk-form4_1685992218.xml · nonDerivative · entry 1

HOUDE LOVAS KATRINA · CIK 0001269294 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,352

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date).

SEC source: 0001628280-23-020826 · wk-form4_1685992025.xml · nonDerivative · entry 1

OBUS NELSON · CIK 0001017043 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,133

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date).

SEC source: 0001628280-23-020822 · wk-form4_1685991739.xml · nonDerivative · entry 1

Schechter Joshua · CIK 0001336601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,113

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date).

SEC source: 0001628280-23-020584 · wk-form4_1685661153.xml · derivative · entry 2

Diradoorian Raymond H · CIK 0001352121 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,474 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.exercise_date: The restricted stock units vested on May 31, 2023.

F2 · derivative.expiration_date: The restricted stock units vested on May 31, 2023.

SEC source: 0001628280-23-020584 · wk-form4_1685661153.xml · nonDerivative · entry 1

Diradoorian Raymond H · CIK 0001352121 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,242

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: The restricted stock units vested on May 31, 2023.

SEC source: 0001628280-23-020580 · wk-form4_1685660536.xml · derivative · entry 2

EDWARDS JEFFREY L · CIK 0001190642 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,474 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.exercise_date: The restricted stock units vested on May 31, 2023.

F2 · derivative.expiration_date: The restricted stock units vested on May 31, 2023.

SEC source: 0001628280-23-020580 · wk-form4_1685660536.xml · nonDerivative · entry 1

EDWARDS JEFFREY L · CIK 0001190642 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,931

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: The restricted stock units vested on May 31, 2023.

SEC source: 0001628280-23-020582 · wk-form4_1685660980.xml · derivative · entry 2

OBUS NELSON · CIK 0001017043 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,474 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.exercise_date: The restricted stock units vested on May 31, 2023.

F2 · derivative.expiration_date: The restricted stock units vested on May 31, 2023.

SEC source: 0001628280-23-020582 · wk-form4_1685660980.xml · nonDerivative · entry 1

OBUS NELSON · CIK 0001017043 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,951

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: The restricted stock units vested on May 31, 2023.

SEC source: 0001628280-23-020578 · wk-form4_1685660228.xml · derivative · entry 2

HOUDE LOVAS KATRINA · CIK 0001269294 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,474 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.exercise_date: The restricted stock units vested on May 31, 2023.

F2 · derivative.expiration_date: The restricted stock units vested on May 31, 2023.

SEC source: 0001628280-23-020578 · wk-form4_1685660228.xml · nonDerivative · entry 1

HOUDE LOVAS KATRINA · CIK 0001269294 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,170

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: The restricted stock units vested on May 31, 2023.

SEC source: 0001628280-23-020576 · wk-form4_1685659799.xml · derivative · entry 2

Barbarosh Craig A. · CIK 0001472457 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · In Trust

Disclosed balance after: 0

Underlying: Common Stock · 9,474 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.exercise_date: The restricted stock units vested on May 31, 2023.

F2 · derivative.expiration_date: The restricted stock units vested on May 31, 2023.

SEC source: 0001628280-23-020576 · wk-form4_1685659799.xml · nonDerivative · entry 1

Barbarosh Craig A. · CIK 0001472457 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · In Trust

Disclosed balance after: 30,337

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: The restricted stock units vested on May 31, 2023.

SEC source: 0001628280-23-020573 · wk-form4_1685659029.xml · derivative · entry 3

Schechter Joshua · CIK 0001336601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,474 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.exercise_date: The restricted stock units vested on May 31, 2023.

F2 · derivative.expiration_date: The restricted stock units vested on May 31, 2023.

SEC source: 0001628280-23-020573 · wk-form4_1685659029.xml · nonDerivative · entry 1

Schechter Joshua · CIK 0001336601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,931

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: The restricted stock units vested on May 31, 2023.

SEC source: 0000921895-23-000268 · form409050040_02022023.xml · nonDerivative · entry 1

Kiper Christopher S · CIK 0001432744 · Director

Legion Partners Asset Management, LLC · CIK 0001560207 · Director

Legion Partners, L.P. I · CIK 0001595909 · Director

Legion Partners, L.P. II · CIK 0001618783 · Director

Legion Partners, LLC · CIK 0001682390 · Director

Legion Partners Holdings, LLC · CIK 0001682389 · Director

White Raymond T. · CIK 0001682494 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,887

F1 · security: This Form 4 is filed jointly by Legion Partners, L.P. I, Legion Partners, L.P. II, Legion Partners, LLC, Legion Partners Asset Management, LLC ("Legion Partners Asset Management"), Legion Partners Holdings, LLC, Christopher S. Kiper and Raymond White (collectively, the "Reporting Persons"). Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F4 · kind: Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.

F4 · shares: Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.

F2 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. (the "Issuer") on a 1 for 1 basis.

F3 · price: The restricted stock units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock.

F4 · balance_after: Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.

F4 · ownership.direct: Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.

F5 · ownership.direct: The securities described in footnotes (2) and (3) represent securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management.

SEC source: 0001628280-23-002099 · wf-form4_167537704631736.xml · derivative · entry 1

HOUDE LOVAS KATRINA · CIK 0001269294 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,554

Underlying: Common Stock · 9,554 shares

Expires not disclosed

F1 · derivative.exercise_price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F1 · price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock.

SEC source: 0001628280-23-002100 · wf-form4_167537706495984.xml · derivative · entry 1

EDWARDS JEFFREY L · CIK 0001190642 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,554

Underlying: Common Stock · 9,554 shares

Expires not disclosed

F1 · derivative.exercise_price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F1 · price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock.

SEC source: 0001628280-23-002098 · wf-form4_167537702928650.xml · derivative · entry 1

OBUS NELSON · CIK 0001017043 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,554

Underlying: Common Stock · 9,554 shares

Expires not disclosed

F1 · derivative.exercise_price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F1 · price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock.

SEC source: 0001628280-23-002097 · wf-form4_167537701261314.xml · derivative · entry 1

Calloway Nathaniel · CIK 0001952771 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,981

Underlying: Common Stock · 3,981 shares

Expires not disclosed

F1 · derivative.exercise_price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F1 · price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock.

SEC source: 0001628280-23-002096 · wf-form4_167537698735747.xml · derivative · entry 1

Schechter Joshua · CIK 0001336601 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,554

Underlying: Common Stock · 9,554 shares

Expires not disclosed

F1 · derivative.exercise_price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F1 · price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock.

SEC source: 0001628280-23-002095 · wf-form4_167537696898838.xml · derivative · entry 1

Diradoorian Raymond H · CIK 0001352121 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,554

Underlying: Common Stock · 9,554 shares

Expires not disclosed

F1 · derivative.exercise_price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F1 · price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock.

SEC source: 0001628280-23-002094 · wf-form4_167537694667098.xml · derivative · entry 1

Barbarosh Craig A. · CIK 0001472457 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · In Trust

Disclosed balance after: 9,554

Underlying: Common Stock · 9,554 shares

Expires not disclosed

F1 · derivative.exercise_price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F1 · price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock.

SEC source: 0001628280-23-001478 · wf-form4_167459556288769.xml · derivative · entry 2

Diradoorian Raymond H · CIK 0001352121 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,768 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · shares: The restricted stock units were granted on January 20, 2022.

F3 · derivative.exercise_date: The restricted stock units vested on January 20, 2023.

F3 · derivative.expiration_date: The restricted stock units vested on January 20, 2023.

SEC source: 0001628280-23-001478 · wf-form4_167459556288769.xml · nonDerivative · entry 1

Diradoorian Raymond H · CIK 0001352121 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,768

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

SEC source: 0001104659-23-003137 · tm233102-2_4seq1.xml · derivative · entry 3

WYNNEFIELD PARTNERS SMALL CAP VALUE LP I · CIK 0001251565 · 10% owner

WYNNEFIELD PARTNERS SMALL CAP VALUE LP · CIK 0000899083 · 10% owner

WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND LTD · CIK 0001030806 · 10% owner

WYNNEFIELD CAPITAL MANAGEMENT LLC · CIK 0001056835 · 10% owner

WYNNEFIELD CAPITAL INC · CIK 0001251567 · 10% owner

Wynnefield Capital, Inc. Profit Sharing Plan · CIK 0001289453 · 10% owner

OBUS NELSON · CIK 0001017043 · 10% owner

LANDES JOSHUA · CIK 0001251568 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 650

Underlying: Common Stock · 92,857 shares

Expires not disclosed

F1 · derivative.exercise_price: Subject to adjustment, as described in the Certificate of Designations of the Series A Convertible Preferred Stock, par value $0.001 per share (the "Convertible Preferred Stock") filed by Lifecore Biomedical, Inc. (the "Company") with the Delaware Secretary of State on January 9, 2023 (the "Certificate of Designation").

F2 · derivative.exercise_date: The shares of Convertible Preferred Stock are convertible into shares of the Company's Common Stock, $0.001 par value per share (the "Common Stock") upon the events specified in the Certificate of Designation.

F2 · derivative.expiration_date: The shares of Convertible Preferred Stock are convertible into shares of the Company's Common Stock, $0.001 par value per share (the "Common Stock") upon the events specified in the Certificate of Designation.

F3 · derivative.underlying_shares: Represents the number of shares of Common Stock issuable upon conversion of the Convertible Preferred Stock on the date of the reported transaction. Each holder of shares of Convertible Preferred Stock shall be entitled to convert all or any portion of the Conversion Amount (as defined in the Certificate of Designation) into that number of shares of Common Stock divided by the Conversion Price (as defined in the Certificate of Designation), initially $7.00, subject to the adjustments and limitations set forth in the Certificate of Designation, including, without limitation, the Beneficial Ownership Limit and the Exchange Cap (each as defined in the Certificate of Designation).

F4 · derivative.underlying_shares: The shares of Convertible Preferred Stock accrue dividends at the rate of 7.5% per annum (on the basis of a 360-day calendar year) on the Stated Value (as defined in the Certificate of Designation), as specified in the Certificate of Designation. To the extent such dividends are paid in-kind, the number of shares of Convertible Preferred Stock and the shares of Common Stock underlying such Convertible Preferred Stock will increase accordingly.

F4 · balance_after: The shares of Convertible Preferred Stock accrue dividends at the rate of 7.5% per annum (on the basis of a 360-day calendar year) on the Stated Value (as defined in the Certificate of Designation), as specified in the Certificate of Designation. To the extent such dividends are paid in-kind, the number of shares of Convertible Preferred Stock and the shares of Common Stock underlying such Convertible Preferred Stock will increase accordingly.

F7 · ownership.nature: The Reporting Person has an indirect beneficial ownership interest in the securities, which are directly beneficially owned by Wynnefield Small Cap Value Offshore Fund, Ltd., as members of a group under Section 13(d) of the Exchange Act. Wynnefield Small Cap Value Offshore Fund, Ltd., which maintains offices at the same address as the Reporting Person, is filing this statement jointly with the Reporting Person. Wynnefield Capital, Inc. as the sole investment manager of Wynnefield Small Cap Value Offshore Fund, Ltd., has an indirect beneficial ownership interest in the securities that Wynnefield Small Cap Value Offshore Fund, Ltd. directly beneficially owns. Nelson Obus and Joshua Landes, as principal executive officers of Wynnefield Capital, Inc., have an indirect beneficial ownership interest in the securities that Wynnefield Small Cap Value Offshore Fund, Ltd. directly beneficially owns.

SEC source: 0001104659-23-003137 · tm233102-2_4seq1.xml · derivative · entry 2

WYNNEFIELD PARTNERS SMALL CAP VALUE LP I · CIK 0001251565 · 10% owner

WYNNEFIELD PARTNERS SMALL CAP VALUE LP · CIK 0000899083 · 10% owner

WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND LTD · CIK 0001030806 · 10% owner

WYNNEFIELD CAPITAL MANAGEMENT LLC · CIK 0001056835 · 10% owner

WYNNEFIELD CAPITAL INC · CIK 0001251567 · 10% owner

Wynnefield Capital, Inc. Profit Sharing Plan · CIK 0001289453 · 10% owner

OBUS NELSON · CIK 0001017043 · 10% owner

LANDES JOSHUA · CIK 0001251568 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,040

Underlying: Common Stock · 148,571 shares

Expires not disclosed

F1 · derivative.exercise_price: Subject to adjustment, as described in the Certificate of Designations of the Series A Convertible Preferred Stock, par value $0.001 per share (the "Convertible Preferred Stock") filed by Lifecore Biomedical, Inc. (the "Company") with the Delaware Secretary of State on January 9, 2023 (the "Certificate of Designation").

F2 · derivative.exercise_date: The shares of Convertible Preferred Stock are convertible into shares of the Company's Common Stock, $0.001 par value per share (the "Common Stock") upon the events specified in the Certificate of Designation.

F2 · derivative.expiration_date: The shares of Convertible Preferred Stock are convertible into shares of the Company's Common Stock, $0.001 par value per share (the "Common Stock") upon the events specified in the Certificate of Designation.

F3 · derivative.underlying_shares: Represents the number of shares of Common Stock issuable upon conversion of the Convertible Preferred Stock on the date of the reported transaction. Each holder of shares of Convertible Preferred Stock shall be entitled to convert all or any portion of the Conversion Amount (as defined in the Certificate of Designation) into that number of shares of Common Stock divided by the Conversion Price (as defined in the Certificate of Designation), initially $7.00, subject to the adjustments and limitations set forth in the Certificate of Designation, including, without limitation, the Beneficial Ownership Limit and the Exchange Cap (each as defined in the Certificate of Designation).

F4 · derivative.underlying_shares: The shares of Convertible Preferred Stock accrue dividends at the rate of 7.5% per annum (on the basis of a 360-day calendar year) on the Stated Value (as defined in the Certificate of Designation), as specified in the Certificate of Designation. To the extent such dividends are paid in-kind, the number of shares of Convertible Preferred Stock and the shares of Common Stock underlying such Convertible Preferred Stock will increase accordingly.

F4 · balance_after: The shares of Convertible Preferred Stock accrue dividends at the rate of 7.5% per annum (on the basis of a 360-day calendar year) on the Stated Value (as defined in the Certificate of Designation), as specified in the Certificate of Designation. To the extent such dividends are paid in-kind, the number of shares of Convertible Preferred Stock and the shares of Common Stock underlying such Convertible Preferred Stock will increase accordingly.

F6 · ownership.nature: The Reporting Person has an indirect beneficial ownership interest in the securities, which are directly beneficially owned by Wynnefield Partners Small Cap Value, L.P., as members of a group under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Wynnefield Partners Small Cap Value, L.P., which maintains offices at the same address as the Reporting Person, is filing this statement jointly with the Reporting Person. Wynnefield Capital Management, LLC, as the sole general partner of Wynnefield Partners Small Cap Value, L.P., has an indirect beneficial ownership interest in the securities that Wynnefield Partners Small Cap Value L.P. directly beneficially owns. Nelson Obus and Joshua Landes, as co-managing members of Wynnefield Capital Management, LLC, have an indirect beneficial ownership interest in the securities that Wynnefield Partners Small Cap Value, L.P. directly beneficially owns.

SEC source: 0001104659-23-003137 · tm233102-2_4seq1.xml · derivative · entry 1

WYNNEFIELD PARTNERS SMALL CAP VALUE LP I · CIK 0001251565 · 10% owner

WYNNEFIELD PARTNERS SMALL CAP VALUE LP · CIK 0000899083 · 10% owner

WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND LTD · CIK 0001030806 · 10% owner

WYNNEFIELD CAPITAL MANAGEMENT LLC · CIK 0001056835 · 10% owner

WYNNEFIELD CAPITAL INC · CIK 0001251567 · 10% owner

Wynnefield Capital, Inc. Profit Sharing Plan · CIK 0001289453 · 10% owner

OBUS NELSON · CIK 0001017043 · 10% owner

LANDES JOSHUA · CIK 0001251568 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,560

Underlying: Common Stock · 222,857 shares

Expires not disclosed

F1 · derivative.exercise_price: Subject to adjustment, as described in the Certificate of Designations of the Series A Convertible Preferred Stock, par value $0.001 per share (the "Convertible Preferred Stock") filed by Lifecore Biomedical, Inc. (the "Company") with the Delaware Secretary of State on January 9, 2023 (the "Certificate of Designation").

F2 · derivative.exercise_date: The shares of Convertible Preferred Stock are convertible into shares of the Company's Common Stock, $0.001 par value per share (the "Common Stock") upon the events specified in the Certificate of Designation.

F2 · derivative.expiration_date: The shares of Convertible Preferred Stock are convertible into shares of the Company's Common Stock, $0.001 par value per share (the "Common Stock") upon the events specified in the Certificate of Designation.

F3 · derivative.underlying_shares: Represents the number of shares of Common Stock issuable upon conversion of the Convertible Preferred Stock on the date of the reported transaction. Each holder of shares of Convertible Preferred Stock shall be entitled to convert all or any portion of the Conversion Amount (as defined in the Certificate of Designation) into that number of shares of Common Stock divided by the Conversion Price (as defined in the Certificate of Designation), initially $7.00, subject to the adjustments and limitations set forth in the Certificate of Designation, including, without limitation, the Beneficial Ownership Limit and the Exchange Cap (each as defined in the Certificate of Designation).

F4 · derivative.underlying_shares: The shares of Convertible Preferred Stock accrue dividends at the rate of 7.5% per annum (on the basis of a 360-day calendar year) on the Stated Value (as defined in the Certificate of Designation), as specified in the Certificate of Designation. To the extent such dividends are paid in-kind, the number of shares of Convertible Preferred Stock and the shares of Common Stock underlying such Convertible Preferred Stock will increase accordingly.

F4 · balance_after: The shares of Convertible Preferred Stock accrue dividends at the rate of 7.5% per annum (on the basis of a 360-day calendar year) on the Stated Value (as defined in the Certificate of Designation), as specified in the Certificate of Designation. To the extent such dividends are paid in-kind, the number of shares of Convertible Preferred Stock and the shares of Common Stock underlying such Convertible Preferred Stock will increase accordingly.

F5 · ownership.direct: Wynnefield Capital Management, LLC, as the sole general partner of the Reporting Person, has an indirect beneficial ownership interest in the securities that the Reporting Person directly beneficially owns. Nelson Obus and Joshua Landes, as co-managing members of Wynnefield Capital Management, LLC, have an indirect beneficial ownership interest in the securities that the Reporting Person directly beneficially owns.

SEC source: 0001193805-23-000038 · e618196_4-lfcr.xml · nonDerivative · entry 1

Kiper Christopher S · CIK 0001432744 · Director

Legion Partners Asset Management, LLC · CIK 0001560207 · Director

Legion Partners, L.P. I · CIK 0001595909 · Director

Legion Partners, L.P. II · CIK 0001618783 · Director

Legion Partners, LLC · CIK 0001682390 · Director

Legion Partners Holdings, LLC · CIK 0001682389 · Director

White Raymond T. · CIK 0001682494 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,906

F1 · security: This Form 4 is filed jointly by Legion Partners, L.P. I, Legion Partners, L.P. II, Legion Partners, LLC, Legion Partners Asset Management, LLC ("Legion Partners Asset Management"), Legion Partners Holdings, LLC, Christopher S. Kiper and Raymond White (collectively, the "Reporting Persons"). Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F4 · kind: Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.

F4 · shares: Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.

F2 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. (the "Issuer") on a 1 for 1 basis.

F3 · price: The restricted stock units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock.

F4 · balance_after: Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.

F4 · ownership.direct: Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.

F5 · ownership.direct: The securities described in footnotes (2) and (3) represent securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management.

SEC source: 0001628280-23-000899 · wf-form4_167347208527160.xml · derivative · entry 1

Calloway Nathaniel · CIK 0001952771 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,906

Underlying: Common Stock · 5,906 shares

Expires not disclosed

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock.

SEC source: 0001104659-23-004663 · tm233686-1_4seq1.xml · nonDerivative · entry 2

WYNNEFIELD PARTNERS SMALL CAP VALUE LP I · CIK 0001251565 · 10% owner

WYNNEFIELD PARTNERS SMALL CAP VALUE LP · CIK 0000899083 · 10% owner

WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND LTD · CIK 0001030806 · 10% owner

WYNNEFIELD CAPITAL MANAGEMENT LLC · CIK 0001056835 · 10% owner

WYNNEFIELD CAPITAL INC · CIK 0001251567 · 10% owner

Wynnefield Capital, Inc. Profit Sharing Plan · CIK 0001289453 · 10% owner

OBUS NELSON · CIK 0001017043 · 10% owner

LANDES JOSHUA · CIK 0001251568 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,438,180

F2 · ownership.nature: The Reporting Person has an indirect beneficial ownership interest in 1,233,865 shares of Common Stock, which are directly beneficially owned by Wynnefield Partners Small Cap Value, L.P., as members of a group under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Wynnefield Partners Small Cap Value, L.P., which maintains offices at the same address as the Reporting Person, is filing this statement jointly with the Reporting Person. Wynnefield Capital Management, LLC, as the sole general partner of Wynnefield Partners Small Cap Value, L.P., has an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Partners Small Cap Value L.P. directly beneficially owns. Nelson Obus and Joshua Landes, as co-managing members of Wynnefield Capital Management, LLC, have an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Partners Small Cap Value, L.P. directly beneficially owns.

F3 · ownership.nature: The Reporting Person has an indirect beneficial ownership interest in 836,965 shares of Common Stock, which are directly beneficially owned by Wynnefield Small Cap Value Offshore Fund, Ltd., as members of a group under Section 13(d) of the Exchange Act. Wynnefield Small Cap Value Offshore Fund, Ltd., which maintains offices at the same address as the Reporting Person, is filing this statement jointly with the Reporting Person. Wynnefield Capital, Inc. as the sole investment manager of Wynnefield Small Cap Value Offshore Fund, Ltd., has an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Small Cap Value Offshore Fund, Ltd. directly beneficially owns. Nelson Obus and Joshua Landes, as principal executive officers of Wynnefield Capital, Inc., have an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Small Cap Value Offshore Fund, Ltd. directly beneficially owns.

F4 · ownership.nature: The Reporting Person has an indirect beneficial ownership interest in 367,350 shares of Common Stock, which are directly beneficially owned by Wynnefield Capital, Inc. Profit Sharing Plan, as members of a group under Section 13(d) of the Exchange Act. Wynnefield Capital, Inc. Profit Sharing Plan, which maintains offices at the same address as the Reporting Person, is filing this Form jointly with the Reporting Person. Mr. Obus and Mr. Landes, as co-trustees, has the power to vote and dispose of Wynnefield Capital, Inc. Profit Sharing Plan's investments in securities and has an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Capital, Inc. Profit Sharing Plan directly beneficially owns.

SEC source: 0001104659-23-004663 · tm233686-1_4seq1.xml · nonDerivative · entry 1

WYNNEFIELD PARTNERS SMALL CAP VALUE LP I · CIK 0001251565 · 10% owner

WYNNEFIELD PARTNERS SMALL CAP VALUE LP · CIK 0000899083 · 10% owner

WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND LTD · CIK 0001030806 · 10% owner

WYNNEFIELD CAPITAL MANAGEMENT LLC · CIK 0001056835 · 10% owner

WYNNEFIELD CAPITAL INC · CIK 0001251567 · 10% owner

Wynnefield Capital, Inc. Profit Sharing Plan · CIK 0001289453 · 10% owner

OBUS NELSON · CIK 0001017043 · 10% owner

LANDES JOSHUA · CIK 0001251568 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,972,853

F1 · ownership.direct: The Reporting Person directly beneficially owns 1,972,853 shares of common stock, $0.001 par value per share ("Common Stock") of Landec Corporation. Wynnefield Capital Management, LLC, as the sole general partner of the Reporting Person, has an indirect beneficial ownership interest in the shares of Common Stock that the Reporting Person directly beneficially owns. Nelson Obus and Joshua Landes, as co-managing members of Wynnefield Capital Management, LLC, have an indirect beneficial ownership interest in the shares of Common Stock that the Reporting Person directly beneficially owns.

SEC source: 0001104659-22-111620 · tm2228861-1_4seq1.xml · nonDerivative · entry 2

WYNNEFIELD PARTNERS SMALL CAP VALUE LP I · CIK 0001251565 · 10% owner

WYNNEFIELD PARTNERS SMALL CAP VALUE LP · CIK 0000899083 · 10% owner

WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND LTD · CIK 0001030806 · 10% owner

WYNNEFIELD CAPITAL MANAGEMENT LLC · CIK 0001056835 · 10% owner

WYNNEFIELD CAPITAL INC · CIK 0001251567 · 10% owner

Wynnefield Capital, Inc. Profit Sharing Plan · CIK 0001289453 · 10% owner

OBUS NELSON · CIK 0001017043 · 10% owner

LANDES JOSHUA · CIK 0001251568 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,155,694

F2 · ownership.nature: The Reporting Person has an indirect beneficial ownership interest in 1,045,541 shares of Common Stock, which are directly beneficially owned by Wynnefield Partners Small Cap Value, L.P., as members of a group under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Wynnefield Partners Small Cap Value, L.P., which maintains offices at the same address as the Reporting Person, is filing this statement jointly with the Reporting Person. Wynnefield Capital Management, LLC, as the sole general partner of Wynnefield Partners Small Cap Value, L.P., has an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Partners Small Cap Value L.P. directly beneficially owns. Nelson Obus and Joshua Landes, as co-managing members of Wynnefield Capital Management, LLC, have an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Partners Small Cap Value, L.P. directly beneficially owns.

F3 · ownership.nature: The Reporting Person has an indirect beneficial ownership interest in 742,803 shares of Common Stock, which are directly beneficially owned by Wynnefield Small Cap Value Offshore Fund, Ltd., as members of a group under Section 13(d) of the Exchange Act. Wynnefield Small Cap Value Offshore Fund, Ltd., which maintains offices at the same address as the Reporting Person, is filing this statement jointly with the Reporting Person. Wynnefield Capital, Inc. as the sole investment manager of Wynnefield Small Cap Value Offshore Fund, Ltd., has an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Small Cap Value Offshore Fund, Ltd. directly beneficially owns. Nelson Obus and Joshua Landes, as principal executive officers of Wynnefield Capital, Inc., have an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Small Cap Value Offshore Fund, Ltd. directly beneficially owns.

F4 · ownership.nature: The Reporting Person has an indirect beneficial ownership interest in 367,350 shares of Common Stock, which are directly beneficially owned by Wynnefield Capital, Inc. Profit Sharing Plan, as members of a group under Section 13(d) of the Exchange Act. Wynnefield Capital, Inc. Profit Sharing Plan, which maintains offices at the same address as the Reporting Person, is filing this Form jointly with the Reporting Person. Mr. Obus and Mr. Landes, as co-trustees, has the power to vote and dispose of Wynnefield Capital, Inc. Profit Sharing Plan's investments in securities and has an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Capital, Inc. Profit Sharing Plan directly beneficially owns.

SEC source: 0001104659-22-111620 · tm2228861-1_4seq1.xml · nonDerivative · entry 1

WYNNEFIELD PARTNERS SMALL CAP VALUE LP I · CIK 0001251565 · 10% owner

WYNNEFIELD PARTNERS SMALL CAP VALUE LP · CIK 0000899083 · 10% owner

WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND LTD · CIK 0001030806 · 10% owner

WYNNEFIELD CAPITAL MANAGEMENT LLC · CIK 0001056835 · 10% owner

WYNNEFIELD CAPITAL INC · CIK 0001251567 · 10% owner

Wynnefield Capital, Inc. Profit Sharing Plan · CIK 0001289453 · 10% owner

OBUS NELSON · CIK 0001017043 · 10% owner

LANDES JOSHUA · CIK 0001251568 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,627,593

F1 · ownership.direct: The Reporting Person directly beneficially owns 1,627,593 shares of common stock, $0.001 par value per share ("Common Stock") of Landec Corporation. Wynnefield Capital Management, LLC, as the sole general partner of the Reporting Person, has an indirect beneficial ownership interest in the shares of Common Stock that the Reporting Person directly beneficially owns. Nelson Obus and Joshua Landes, as co-managing members of Wynnefield Capital Management, LLC, have an indirect beneficial ownership interest in the shares of Common Stock that the Reporting Person directly beneficially owns.

F2 · ownership.direct: The Reporting Person has an indirect beneficial ownership interest in 1,045,541 shares of Common Stock, which are directly beneficially owned by Wynnefield Partners Small Cap Value, L.P., as members of a group under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Wynnefield Partners Small Cap Value, L.P., which maintains offices at the same address as the Reporting Person, is filing this statement jointly with the Reporting Person. Wynnefield Capital Management, LLC, as the sole general partner of Wynnefield Partners Small Cap Value, L.P., has an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Partners Small Cap Value L.P. directly beneficially owns. Nelson Obus and Joshua Landes, as co-managing members of Wynnefield Capital Management, LLC, have an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Partners Small Cap Value, L.P. directly beneficially owns.

F3 · ownership.direct: The Reporting Person has an indirect beneficial ownership interest in 742,803 shares of Common Stock, which are directly beneficially owned by Wynnefield Small Cap Value Offshore Fund, Ltd., as members of a group under Section 13(d) of the Exchange Act. Wynnefield Small Cap Value Offshore Fund, Ltd., which maintains offices at the same address as the Reporting Person, is filing this statement jointly with the Reporting Person. Wynnefield Capital, Inc. as the sole investment manager of Wynnefield Small Cap Value Offshore Fund, Ltd., has an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Small Cap Value Offshore Fund, Ltd. directly beneficially owns. Nelson Obus and Joshua Landes, as principal executive officers of Wynnefield Capital, Inc., have an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Small Cap Value Offshore Fund, Ltd. directly beneficially owns.

F4 · ownership.direct: The Reporting Person has an indirect beneficial ownership interest in 367,350 shares of Common Stock, which are directly beneficially owned by Wynnefield Capital, Inc. Profit Sharing Plan, as members of a group under Section 13(d) of the Exchange Act. Wynnefield Capital, Inc. Profit Sharing Plan, which maintains offices at the same address as the Reporting Person, is filing this Form jointly with the Reporting Person. Mr. Obus and Mr. Landes, as co-trustees, has the power to vote and dispose of Wynnefield Capital, Inc. Profit Sharing Plan's investments in securities and has an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Capital, Inc. Profit Sharing Plan directly beneficially owns.

SEC source: 0001628280-22-022940 · wf-form4_166060256850518.xml · derivative · entry 3

Morberg John D · CIK 0001345964 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires not disclosed

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.

F2 · derivative.expiration_date: Restricted Stock Units will vest on the 3rd anniversary of the grant date and will be automatically settled in shares of common stock.

SEC source: 0001628280-22-022940 · wf-form4_166060256850518.xml · derivative · entry 2

Morberg John D · CIK 0001345964 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,000

Underlying: Common Stock · 12,591 shares

Expires 2029-08-11

SEC source: 0001628280-22-022940 · wf-form4_166060256850518.xml · derivative · entry 1

Morberg John D · CIK 0001345964 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 409

Underlying: Common Stock · 409 shares

Expires 2029-08-11

SEC source: 0001628280-22-022949 · wf-form4_166060352143970.xml · derivative · entry 2

Hall James G · CIK 0001368626 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires not disclosed

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.

F2 · derivative.expiration_date: Restricted Stock Units will vest on the 3rd anniversary of the grant date and will be automatically settled in shares of common stock subject to vesting at a rate of 1 share per unit.

SEC source: 0001628280-22-022949 · wf-form4_166060352143970.xml · derivative · entry 1

Hall James G · CIK 0001368626 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2029-08-11

SEC source: 0001628280-22-021699 · wf-form4_166000334579496.xml · derivative · entry 3

Hall James G · CIK 0001368626 · Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2022-08-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.

F2 · shares: The restricted stock units were granted on August 5, 2019.

F3 · derivative.exercise_date: The restricted stock units vested on August 5, 2022.

SEC source: 0001628280-22-021699 · wf-form4_166000334579496.xml · nonDerivative · entry 2

Hall James G · CIK 0001368626 · Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,096

SEC source: 0001628280-22-021699 · wf-form4_166000334579496.xml · nonDerivative · entry 1

Hall James G · CIK 0001368626 · Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,156

F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.

SEC source: 0001628280-22-019063 · wf-form4_165817814166337.xml · derivative · entry 3

Morberg John D · CIK 0001345964 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,771

Underlying: Common Stock · 9,771 shares

Expires 2029-07-14

SEC source: 0001628280-22-019063 · wf-form4_165817814166337.xml · derivative · entry 2

Morberg John D · CIK 0001345964 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,229

Underlying: Common Stock · 40,229 shares

Expires 2029-07-14

SEC source: 0001628280-22-019063 · wf-form4_165817814166337.xml · derivative · entry 1

Morberg John D · CIK 0001345964 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,123

Underlying: Common Stock · 5,123 shares

Expires not disclosed

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.

F2 · price: Restricted Stock Units will vest on the 3rd anniversary of the grant date and will be automatically settled in shares of common stock.

F2 · derivative.expiration_date: Restricted Stock Units will vest on the 3rd anniversary of the grant date and will be automatically settled in shares of common stock.

SEC source: 0001628280-22-019061 · wf-form4_165817799678454.xml · derivative · entry 2

Hall James G · CIK 0001368626 · Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,755

Underlying: Common Stock · 49,755 shares

Expires 2029-07-14

SEC source: 0001628280-22-019061 · wf-form4_165817799678454.xml · derivative · entry 1

Hall James G · CIK 0001368626 · Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,245

Underlying: Common Stock · 10,245 shares

Expires 2029-07-14

SEC source: 0001628280-22-016491 · wf-form4_165463670638202.xml · derivative · entry 2

Powell Andrew Kenneth William · CIK 0001304113 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,059 shares

Expires 2022-06-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.

F2 · shares: The restricted stock units were granted on June 4, 2021.

F3 · derivative.exercise_date: The restricted stock units vested on June 4, 2022.

F3 · derivative.expiration_date: The restricted stock units vested on June 4, 2022.

SEC source: 0001628280-22-016491 · wf-form4_165463670638202.xml · nonDerivative · entry 1

Powell Andrew Kenneth William · CIK 0001304113 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,477

F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.